Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users
NCT06927401 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2025-04-15
Summary
Clinical Study Overview Feasibility Study Plan (Study 1: Healthy Participants) Study 1- Confirming Flower capsule performance characteristics in detection of retained gastric contents greater than 1.5mL/kg in Healthy volunteers
1\. Study Purpose
a. A controlled, prospective, between-participants study design to assess Flower in detecting the presence or absence of retained gastric contents (RGC), using sedated esophagogastroduodenoscopy (EGD) as the ground truth for an empty stomach and known ingested volume as the ground truth for a fed participant.
2\. Study Endpoints
a. Primary i. Visualization of Retained Gastric Contents b. Secondary i. Gastric mucosal visualization of the seven anatomical landmarks of the stomach (fundus, cardia, lesser gastric curvature, greater gastric curvature, angulus, antrum, and pylorus) ii. Gastric Cleanliness iii. Adverse events defined as capsule retention, capsule aspiration, perforation, nausea, and pain iv. Maximum, tolerated water consumed v. Patient tolerance vi. Exploratory attempts for successful swallowing vii. Exploratory minimum and maximum water volume for optimal Flower performance viii. Time required for gastric examination completion by Flower
Conditions
- Endoscopy, Digestive System
- GLP1-R-related Disease
Interventions
- DEVICE
-
Flower
Flower is a single-use capsule endoscope designed for timely visualization of the human stomach. The patient drinks water to fill the stomach before swallowing the Flower capsule, which transmits wireless video, through an external dongle placed near the patient's abdomen, to a physician's computer or smartphone. Flower is weighted to orientationally bias the capsule upward, meaning that with a few simple position adjustments a complete viewing of the stomach can be achieved approximately 10 minutes. The procedure requires no sedation or equipment other than the Flower System (capsule and dongle). As a simple means of screening, Flower functions equivalent to comparable technologies, but offers advantages of being less invasive and burdensome. Flower has fewer potentially adverse consequences than traditional endoscopy (EGD), and it does not require capital equipment as magnetic endoscopy does. Flower offers the identification and location of bleeding sources in the stomach.
Sponsors & Collaborators
-
Endiatx
collaborator INDUSTRY -
Asian Institute of Gastroenterology, India
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-04-08
- Primary Completion
- 2025-06-30
- Completion
- 2025-08-30
Countries
- India
Study Locations
More Related Trials
-
Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects
NCT03682172 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow
NCT01988545 ·Status: UNKNOWN ·Phase: NA
-
Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans
NCT00876213 ·Status: COMPLETED
-
The Effects of LAF237 on Gastric Function in Type 2 Diabetes
NCT00952991 ·Status: COMPLETED ·Phase: PHASE3
-
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
NCT00537719 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying
NCT04651868 ·Status: COMPLETED ·Phase: NA
-
GLP-1 Signaling in Truncally Vagotomized Subjects
NCT02940184 ·Status: UNKNOWN ·Phase: NA
-
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
NCT00673751 ·Status: UNKNOWN ·Phase: NA
-
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
NCT02042664 ·Status: COMPLETED ·Phase: PHASE3
-
Intestinal Ketone Bodies Interfere With the Glycemic Control
NCT05154461 ·Status: COMPLETED ·Phase: NA
-
GLP-1 on Non-ST-Segment Elevation Myocardial Infarction
NCT02577848 ·Status: UNKNOWN ·Phase: NA
-
Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options
NCT02365740 ·Status: UNKNOWN ·Phase: NA
-
GLP-1 Infusion and Long-Time Fasting
NCT00285896 ·Status: COMPLETED ·Phase: NA
-
Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota
NCT02061124 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
NCT07313813 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The Role of Metformin and Colesevelam in Human GLP-1 Secretion
NCT02050074 ·Status: COMPLETED ·Phase: PHASE4
-
GLP-1 Receptor Expression in CHI
NCT03768518 ·Status: UNKNOWN
-
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion
NCT03018444 ·Status: COMPLETED ·Phase: NA
-
Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus
NCT00603031 ·Status: COMPLETED ·Phase: NA
-
The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects
NCT01579981 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
NCT01509742 ·Status: COMPLETED ·Phase: PHASE1
-
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia
NCT06654219 ·Status: RECRUITING ·Phase: NA
-
Effect of Fasting Recommendations Among Patients Using GLP-1 Receptor Agonists
NCT06839248 ·Status: RECRUITING ·Phase: NA
-
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
NCT06774807 ·Status: COMPLETED ·Phase: NA